1 / 6

Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1- 3 PROTON

Phase 2. Treatment Naïve . Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1- 3 PROTON. Lawitz E, et al. Lancet Infect Dis. 2013;13:401-8. Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3 PROTON Trial: Design. Source: Lawitz E, et al. Lancet Infect Dis. 2013;13:401-8.

marnie
Download Presentation

Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1- 3 PROTON

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 TreatmentNaïve Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3PROTON Lawitz E, et al. Lancet Infect Dis. 2013;13:401-8.

  2. Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3PROTON Trial: Design Source: Lawitz E, et al. Lancet Infect Dis. 2013;13:401-8.

  3. Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3PROTON Trial: Design 0 12 24 48 72 Week + RVR GT 1 SOF (200 mg) +PEG + RBV PEG + RBV n =48 - RVR PEG + RBV + RVR SOF (400 mg) +PEG + RBV PEG + RBV n =47 - RVR PEG + RBV SOF + PEG + RBV n =26 GT 2, 3 SOF + PEG + RBV n = 25 N =14 Drug DosingSofosbuvir (SOF): 400 mg once daily, except as designated in arm that received 200 mg once dailyRibavirin (RBV) weight-based and divided bid: 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kgPeginterferferon alfa-2a (PEG): 180 µg once weekly Source: Lawitz E, et al. Lancet Infect Dis. 2013;13:401-8.

  4. Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3PROTON Trial: Design PROTON: SVR 24 41/48 42/47 15/26 23/25 Genotype 1 Genotype 2 Source: Lawitz E, et al. Lancet Infect Dis. 2013;13:401-8.

  5. Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3PROTON Trial: Conclusions Source: Lawitz E, et al. Lancet Infect Dis. 2013;13:401-8.

  6. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related